Sedation with sevoflurane in postoperative cardiac surgery: influence on troponin T and creatinine values

J.M. Marcos-Vidal, R. González, C. García, C. Soria, M. Galiana, B. De Prada
Department Anaesthesia and Reanimation, Hospital of Leon, Leon, Spain

ABSTRACT

Introduction: To compare the potential beneficial effects on markers of myocardial injury (troponin T) and renal function between sedation with sevoflurane vs propofol after cardiac surgery using extracorporeal cardiopulmonary bypass.

Methods: A prospective study with sequential selection of patients undergoing coronary or coronary and valve cardiac surgery. Intraoperative anesthesia consisted in sevoflurane and remifentanil, while in the postoperative period patients were divided in two groups to receive sedation with either sevoflurane through the AnaConDa© system or propofol. The patients were sedated during a minimum of 120 minutes. Markers of myocardial injury and plasmatic creatinine were measured 4, 12, 24, and 48 hours after surgery.

Results: Data from 129 patients, 62 sedated with propofol and 67 with sevoflurane, were analyzed. The analysis of the troponin T levels showed differences 12 and 48 hours after admission. Mean values at 12 hours were 0.89 (standard deviation 0.55) µg.L-1 in the propofol group and 0.69 (standard deviation 0.40) µg. L-1 in the sevoflurane group (p=0.026). TnT levels at 48 hours were 0.60 (standard deviation 0.46) µg.L-1 in the propofol group and 0.37 (standard deviation 0.26) µg.L-1 in the sevoflurane group (p=0.007). No differences were found in the groups in the creatinine levels before discharge.

Conclusions: The post-operative sedation with sevoflurane after cardiac surgery with cardiopulmonary bypass is a valid alternative to propofol. It does not increase the number of side effects related to kidney damage in patients with no prior renal disease, leading to reduced troponin T levels 12 and 48 hours after admission.

Keywords: sedation, cardiac surgery, postoperative care, sevoflurane, propofol.

INTRODUCTION

The first descriptions of the anti-ischemic effects of volatile anesthetics date back to 1976, when Bland and Lowestein (1) reported that halothane decreased ST segment changes in dogs. Clinically, the cardioprotective effects of volatile anesthetics have mainly been studied in cardiac surgery, differentiating between cardiac preconditioning (2) and postconditioning (3) depending on the time of administration of the anesthetic agent. The effects on myocardium of these forms of administration of volatile anesthetics have been controversial and less conclusive than those reported at experimental level (4). However, the most significant results depend on the time when the anesthetic gas is administered: these are more evident when it is...
given throughout the surgical procedure, decreasing the cardiac biomarker levels and improving the myocardial function (5-9). Today, the use of volatile anesthetics is no longer conditioned by the availability of an anesthesia station with a vaporizer. The development of the Anaesthetic Conserving Device, which may be described as a minivaporizer consisting of an activated charcoal membrane that allows for anesthetic absorption and reuse (10), permits the use of anesthetic gases (sevoflurane and isoflurane) with the usual ventilators in the critical care units. This makes possible the use of volatile anesthetics during the postoperative period (11).

The purpose of this study is therefore to assess whether the extended administration of a volatile anesthetic (sevoflurane) during the postoperative period has beneficial effects on markers of myocardial injury (troponin T) when compared with a sedation with propofol.

**METHODS**

The study was approved by the Ethics Committee of Leon University Hospital, Leon, Spain on 24 May 2011. Written consent for study participation was obtained from 144 patients undergoing cardiac surgery with cardiopulmonary bypass (CPB). This was a prospective study conducted in a tertiary hospital. Sequentially selected patients were alternatively assigned to the study groups. Sample size calculation for an expected standard deviation (SD) in both groups of 0.7, to detect a means difference in troponin T (cTnT) levels of 0.5 µg.L⁻¹ (95% confidence level, 80% power), was 63 patients per group. 72 patients per group were enrolled to provide for potential losses.

**Inclusion and exclusion criteria.** Inclusion criteria were age over 18 years, coronary or mixed (valve + coronary) surgery using CPB, and a minimum sedation period of 120 minutes. Patients with a history of malignant hyperthermia, propofol allergy, surgery without CPB, urgent surgery, and cryoablation surgery were excluded. Finally, patients with preoperative creatinine levels higher than 1.5 mg.dL⁻¹ in a blood sample drawn within 24 hours of surgery were excluded from the study.

**Intraoperative period.** Patients were premedicated with a benzodiazepine the night before the procedure and with intramuscular morphine (35 mg) in the morning of surgery. In accordance with the standard procedure for cardiac surgery with CPB, anesthesia was induced using midazolam (0.07 mg.kg⁻¹), fentanyl (4 µg.kg⁻¹), etomidate (3.5 mg.kg⁻¹), and cisatracurium (0.2 mg.kg⁻¹). Remifentanil and sevoflurane were used to maintain anesthesia, with a target bispectral index (BIS) value ranging from 40 to 60. During CPB, sevoflurane was used with the same target BIS.

**Postoperative period.** Interventions in the intensive care unit (ICU) included:

- **Propofol (P) sedation group.** Propofol infusion at 2 mg.kg⁻¹.h⁻¹, with a loading dose of 1 mg.kg⁻¹ if required to achieve a BIS ranging from 60 to 80. The maintenance rate was adjusted between 1 and 4 mg.kg⁻¹.h⁻¹ to maintain BIS values ranging from 60 to 80. Remifentanil 0.050.1 µg.kg⁻¹.min⁻¹ was concomitantly administered.

- **Sevoflurane (S) sedation group.** Sedation with sevoflurane through the Anesthetic Conserving Device (AnaConDa®, Sedana Medical, Sundbyberg, Sweden), administered at an infusion rate ranging from 3 and 8 mL.h⁻¹, to a target BIS ranging from 60 to 80. Remifentanil 0.050.1 µg.kg⁻¹.min⁻¹ was concomitantly administered. This group also underwent end-tidal sevoflurane monitoring through a MaxTm® monitor, maintaining a value ranging from 0.5 to 1 as target end-tidal sevoflurane sedation.
Criteria for extubation were a discharge of less than 100 mL through the thoracic drainages for two consecutive hours, with a bladder temperature of at least 36.5ºC. Before extubation, both groups were administered ondansetron, morphine (35 mg), and acetaminophen.

Variables recorded included age, sex, weight (kg), height (cm), type of surgery (coronary, mixed), operating time (min), CPB time (min), EuroSCORE II, preoperative ejection fraction (normal, depressed, severely depressed), sedation group, sedation time, creatinine (mg.dL⁻¹), CK, CK/MB, cTnT at 4, 12, 24, and 48 hours after the admission in the ICU, creatinine before surgery, at admission in the hospital, 4, 12, and 24 hours after the admission in the ICU and at hospital discharge, requirement of inotropics, vasoconstrictors, or vasopressors during the stay in the ICU, arrhythmia during ICU stay, time of stay in the ICU, length of postoperative stay, and patient vital status 30 days after surgery.

**Statistical analysis.** The Normal distribution of data was verified using a Kolmogorov-Smirnov test. The demographic variables, operating and hospital stay times, and study variables were analyzed using a Student’s t test for independent data. The use of vasoactive agents and the occurrence of cardiac arrhythmia were analyzed using a Chi-square test. The SPSS 17.0 statistical software (SPSS Inc., Chicago, IL) was used for analysis.

**RESULTS**

144 patients were initially enrolled in the study. 15 patients were excluded: 10 patients in the propofol group (5 patients had a preoperative creatinine > 1.5 mg.dL⁻¹, 3 patients underwent cryoablation and 2 patients needed urgent surgery) and 5 patients in the sevoflurane group (3 patients had a preoperative creatinine > 1.5 mg.dL⁻¹ and 2 patients underwent a cryoablation). Therefore, the data from 129 patients, 62 in the propofol group and 67 in the sevoflurane group, were finally analyzed.

There were no differences between the groups in demographic and surgical risk data reflected by EuroSCORE II (Table 1). Coronary bypass surgery was performed in 46.8% of patients in the propofol group and in 49.3% of patients in the sevoflurane group. All other surgical procedures were mixed (coronary + valve surgery). The ejection fraction, as estimated by cardiac catheterization, was normal in 79% of patients in the propofol group and in

|                | Propofol N = 62 | Sevoflurane N = 67 | p  |
|----------------|----------------|-------------------|----|
| Mean Age (standard deviation), years | 69.24 (11.85) | 69.13 (10.52) | 0.957 |
| Men (%)          | 67.7           | 77.6              | 0.208 |
| BMI (standard deviation), kg.m⁻²·⁻¹ | 27.70 (3.78) | 28.05 (3.46) | 0.589 |
| Mean Euroscore II (standard deviation) | 6.91 (5.71) | 6.17 (4.45) | 0.408 |
| Preoperative Haemoglobin (standard deviation), mg.dL⁻¹ | 13.88 (1.72) | 13.87 (1.57) | 0.467 |
| Haematocrit (standard deviation)       | 40.47 (5.21) | 40.96 (4.65) | 0.577 |

BMI = Body mass index
74.6% of patients in the sevoflurane group. It was severely depressed in 4.8% and 1.5% of patients in the propofol group and in the sevoflurane group respectively. During the stay in the recovery room, no differences were found among the groups in the proportion of patients who needed the administration of norepinephrine, dobutamine, or intravenous vasodilating agents. There were no differences in the number of patients who developed an atrial fibrillation during this period (Table 2). There were no differences among the groups in the intraoperative time, the time

### Table 2 - Comparison between the use of dobutamine, norepinephrine, nitroglycerine and atrial fibrillation development during the stay in the intensive care unit. We did not find any statistically significant differences in the cut-off points at admission, 4, 12, 24 and 48 hours of monitoring.

|                          | Propofol n = 62 | Sevoflurane n = 67 | Chi-square p |
|--------------------------|-----------------|--------------------|--------------|
| Admission Norepinephrine (%) | 22.6            | 10.4               | 0.062        |
| Admission Dobutamine (%)   | 21              | 16.4               | 0.507        |
| Admission Nitroglycerine (%) | 6.5            | 11.9               | 0.284        |
| 4 hours Noradrenaline (%)  | 21              | 11.9               | 0.165        |
| 4 hours Dobutamine (%)     | 19.4            | 17.9               | 0.833        |
| 4 hours Nitroglycerine (%) | 11.3            | 17.9               | 0.289        |
| 12 hours Noradrenaline (%) | 14.5            | 7.6                | 0.209        |
| 12 hours Dobutamine (%)    | 19.4            | 18.2               | 0.865        |
| 12 hours Nitroglycerine (%) | 8.1             | 15.2               | 0.213        |
| 24 hours Noradrenaline (%) | 10             | 3                  | 0.109        |
| 24 hours Dobutamine (%)    | 18.3            | 12.1               | 0.330        |
| 24 hours Nitroglycerine (%) | 5              | 1.5                | 0.265        |
| 48 hours Noradrenaline (%) | 1.9             | 1.6                | 0.882        |
| 48 hours Dobutamine (%)    | 13.5            | 4.7                | 0.094        |
| 48 hours Nitroglycerine (%) | 3.8             | 1.6                | 0.441        |
| Intraoperative cardioversion (%) | 53.2       | 56.7               | 0.690        |
| Atrial Fibrillation in ICU (%) | 27.4          | 23.9               | 0.654        |

ICU: intensive care unit

### Table 3 - Mean duration of anesthesia, cardiopulmonary bypass time, sedation, time in intensive care unit and time between surgery and hospital discharge.

|                          | Propofol N = 62 | Sevoflurane N = 67 | p  |
|--------------------------|-----------------|--------------------|----|
| Mean Duration Anesthesia (standard deviation), minutes | 338.98 (87.19)   | 366.28 (79.14)     | 0.065 |
| CPB time (standard deviation), minutes            | 117.47 (33.78)   | 124.04 (37.15)     | 0.296 |
| Mean Duration Sedation (standard deviation), minutes | 306.13 (156.03)  | 285.82 (148.75)    | 0.451 |
| Time ICU (standard deviation), hours                | 46.76 (31.42)    | 44.09 (30.35)      | 0.625 |
| Time hospital before surgery (standard deviation), days | 7.53 (7.35)      | 6.51 (2.94)        | 0.117 |

ICU: intensive care unit
Sedation with sevoflurane in postoperative cardiac surgery

Figure 1 - Troponin T on admission, 4, 12, 24 and 48 hours in patients sedated with propofol and sevoflurane. It also shows the peak troponin T and the difference between the peak value of troponin T and troponin on admission. Statistically significant differences at 12 (p=0.026) and 48 hours (p=0.007).

TnT peak - TnT 0 was also statistically different p=0.027.

from induction of to recovery from anesthesia, or the time of extracorporeal circulation (Table 3). The proportion of patients who required cardioversion after removal of CPB was 53.2% in the propofol group and 56.7% in the sevoflurane group, with a mean of 1.06 (SD 1.30) shocks in the first group and 1.10 (SD 1.38) in the second group (p = 0.866).

With regards to the objective of the study, differences in TnT levels were found at 12 hours, with a mean of 0.89 (SD 0.55) µg. L⁻¹ in the propofol group versus 0.69 (SD 0.40) µg. L⁻¹ in the sevoflurane group, with a difference between means of 0.19 (95% CI 0.02 to 0.34), p = 0.026. There were differences at48 hours with a mean TnT level in the propofol group of 0.60 (SD0.46) µg. L⁻¹ versus 0.37 (SD 0.26) µg. L⁻¹ in the sevoflurane group, with a difference between means of 0.22 (95% CI 0.06 to 0.39), p = 0.007.

The difference between the peak level of TnT and the level of TnT at the time of admission (shown as TnT peak - TnT 0 in Figure 1) was also different in each group: 0.67 (SD 0.44) with propofol and 0.51 (SD 0.36) with sevoflurane, with a difference between means of 0.16 (95% CI 0.07 to 0.19), p = 0.027.

No differences were seen between the groups in the levels of CK, CKMB, and creatinine at the time of admission or 4, 12, 24, and 48 hours after admission (Figures 2, 3, 4).

The levels of plasmatic creatinine before surgery and at hospital discharge, the difference between the peak and preoperative creatinine and the difference between the plasmatic creatinine at hospital discharge
Figure 2 - Creatine kinase on admission, 4, 12, 24 and 48 hours in patients sedated with propofol and sevoflurane. No statistically significant differences in any of the monitoring points. CK = Creatine kinase.

Figure 3 - Creatine kinase MB fraction on admission, 4, 12, 24 and 48 hours of intensive care unit stay in patients sedated with propofol and sevoflurane. No statistically significant differences in any of the monitoring points. CK MB = Creatine kinase MB fraction.
and before surgery showed no differences between the groups (Figure 4).
No differences were found among the groups in the length of hospital stay and in the stay from surgery to discharge. No deaths occurred in any of the groups in the 30 days following surgery.

**DISCUSSION**

In patients undergoing coronary revascularization surgery, either alone or combined with valvular surgery, the continuous postoperative sedation with sevoflurane decreased TnT levels at 12 and 48 hours after surgery when compared with the administration of propofol during sedation.

These data disagree with those reported by Hellstrom et al. (12), who found no differences in the levels of TnT 12 hours after coronary surgery alone. Prior studies have shown that the raise in the TnT levels following cardiac surgery with cardiopulmonary bypass was associated to increased mortality and longer ICU stay (13, 14).

By contrast, no statistically significant differences were seen in our study in terms of length of ICU or hospital stay, which should lead us to question whether the differences (0.19 and 0.22 µg. L1) found in our study have a clinical - and not just statistical - impact. In any case, attention should be called to the trend we identified (1 day of difference in the length of stay from surgery to hospital discharge favoring patients sedated with sevoflurane). Such difference was not statistically significant, possibly because of an inadequate sample size for this objective, but it would agree with the studies where troponin was found to be a predictor for surgical outcome. According to these findings, we would like to emphasize the differences obtained in...
the time of postoperative sedation, which is longer in the propofol group (mean difference 20 minutes), although they are not statistically significant and would not cause any change in the TnT plasmatic levels. The shorter time until recovery after sedation with sevoflurane, as obtained in previous studies, could be an influencing factor for these results (15).

We must remember that cardiac surgery constitutes a suitable, but still suboptimal model for the study of potential cardioprotective effects of anesthetic agents (16). The perioperative morbidity has decreased significantly, so it becomes increasingly difficult to prove that an additional protective measure will result in a change in perioperative morbidity and mortality (17) because we would need larger sample sizes. Different meta-analyses (18, 19) have shown that the use of anesthetic agents decreases the use of vasopressors. The statistical analysis of our study sample showed no significant quantitative differences in the use of norepinephrine, dobutamine, and nitroglycerin for the first 48 hours after admission. However, the analysis of the data did show a trend to a decreased use of both norepinephrine and dobutamine and to an increased use of nitroglycerin in the sevoflurane group. This trend may condition the levels of TnT, and makes us wonder whether the use of vasopressors and vasodilators might be conditioned by the sedative agent used. It should be noted that there were no target mean blood pressure levels considered in the design of the study, and that the use of vasopressors was a decision of the anesthesiologist in charge. The use of vasopressor or vasodilator agents was recorded, but not the drug doses. Renal toxicity is a critical aspect when assessing long-term exposure to sevoflurane. In the 70s, following marketing of methoxylflurane, it was postulated that a plasma level of this drug >50 µmol.L⁻¹ resulted in kidney damage (20). After that, it was questioned whether this threshold of 50 µmol.L⁻¹ could be extrapolated from all anesthetic gases (21, 22). Damage caused by methoxyflurane was partly attributed to intrarenal metabolism, which does not occur with other anesthetic gases such as sevoflurane. Levels of inorganic fluorine remains high until 48 hours after administration of sevoflurane. Data reported here show creatinine levels as a marker of kidney damage during the first 48 hours, with a biochemical measurement available on the day of hospital discharge.

There was no difference among the two groups in the creatinine levels or in the peak creatinine levels at admission. A creatinine level >1.5 mg.dL⁻¹ within 24 hours of surgery was an exclusion criterion. This, combined with a mean pre-operative hemoglobin >13 mg.dL⁻¹ (another determinant factor for the occurrence of acute renal failure after cardiac surgery (23)), would be the reason for the low incidence of acute renal failure and for the fact that no patient required extrarenal clearance procedures. The CPB time, the other factor especially associated to renal failure, did not differ among the groups. Sevoflurane may therefore be used in patients with prior kidney damage to assess its results in this patient group.

Continuous administration of sevoflurane in the postoperative period is permitted by the AnaConDa® (Anesthetic Conserving Device) system, which has an efficiency in terms of sevoflurane consumption similar to a circular circuit with fresh gas at 1.5 L.min⁻¹ (24). The AnaConDa® may be used with any ICU ventilator, and it has been shown to be a valid alternative to a conventional vaporizer when no anesthesia station is available (25).

A critical aspect in the use of this device is environmental pollution, which respects the limits established by the National Insti-
Sedation with sevoflurane in postoperative cardiac surgery

In conclusion, continuous sedation with sevoflurane in the postoperative period of coronary or mixed (valvular and coronary) surgery may not only be considered as a valid alternative to propofol, but it might also decrease cardiac TnT levels. No differences were found in renal function when levels of creatinine were measured.

REFERENCES

1. Bland JH, Lowenstein E. Halothane-induced decrease in experimental myocardial ischemia in the non-failing canine heart. Anesthesiology 1976; 45: 287-93.
2. Julier K, da Silva R, García C, et al. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled multicenter study. Anesthesiology 2003; 99: 1315-27.
3. Pagel PS. Postconditioning by volatile anesthetics: salvaging ischemic myocardium at reperfusion by activation of prosurvival signaling. J Cardiothorac Vasc Anesth 2008; 22: 753-65.
4. De Hert SG. Anesthetic preconditioning: how important is it in today’s cardiac anesthesia? J Cardiothorac Vasc Anesth 2006; 20: 473-6.
5. De Hert SG, ten Broecke PW, Mertens E, et al. Sevoflurane but not propofol preserves myocardial function in coronary surgery patients. Anesthesiology 2002; 97: 42-9.
6. De Hert SG, Cromheecke S, ten Broecke PW, et al. Effects of propofol, desflurane, and sevoflurane on recovery of myocardial function after coronary surgery in elderly high-risk patients. Anesthesiology 2003; 99: 314-23.
7. Conzen PF, Fischer S, Detter C, et al. Sevoflurane provides greater protection of the myocardium than propofol in patients undergoing offpump coronary artery bypass surgery. Anesthesiology 2003; 99: 826-33.
8. Bein B, Renner J, Caliebe D, et al. Sevoflurane but not propofol preserves myocardial function during minimally invasive direct coronary artery bypass surgery. Anesth Analg 2005;100: 610-6.
9. De Hert SG, Van der Linden Pj, Cromheecke S, et al. Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration. Anesthesiology 2004; 101: 299-310.
10. Soukup J, Scharff K, Kubosch K, et al. State of the art: Sedation concepts with volatile anesthetics in critically ill patients. J Crit Care 2009; 24: 535-44.
11. Sturesson LW, Johansson A, Bodelsson M, et al. Wash-in kinetics for sevoflurane using a disposable delivery system (AnaConDa®) in cardiac surgery patients. Br J Anaesth 2009; 102: 470-6.
12. Hellstrom J, Owall A, Bergstrom J, et al. Cardiac outcome after sevoflurane versus propofol sedation following coronary bypass surgery: a pilot study. Acta Anaesthesiol Scand. 2011; 55: 460-7.
13. Mohammed AA, Agnihotri AK, van Kimmenade RR, et al. Prospective, comprehensive assessment of cardiac troponin T testing after coronary artery bypass graft surgery. Circulation 2009; 120: 843-50.
14. Nesher N, Alghamdi AA, Singh SK, et al. Troponin after cardiac surgery: a predictor or a phenomenon? Ann Thorac Surg. 2008;85: 1348-54.
15. Hellström J, Öwall A, Sackey PV. Wake-up times following sedation with sevoflurane versus propofol after cardiac surgery. Scand Cardiovasc J 2012; 46: 262-8.
16. De Hert SG, Preckel B, Hollmann MW, et al. Drugs mediating myocardial protection. Eur J Anaesthesiol 2009; 26: 985-95.
17. De Hert SG. Is anaesthetic cardioprotection clinically relevant? Another futile search for a magic bullet? Eur J Anaesthesiol 2011; 28: 616-7.
18. Symons JA, Myles PS. Myocardial protection with volatile anaesthetic agents during coronary artery bypass surgery: a meta-analysis. Br J Anaesth 2006; 97: 127-36.
19. Landoni G, Biondi-Zoccai GG, Zangrillo A, et al. Desflurane and sevoflurane in cardiac surgery: a meta-analysis of randomized clinical trials. J Cardiothorac Vasc Anesth. 2007; 21: 502-11.
20. Cousins MJ, Mazze RI. Methoxyflurane nephotoxicity. A study of dose response in man. JAMA 1973; 325: 1611-6.
21. Röhm KD, Mengistu AM, Boldt J, et al. Renal integrity in sevoflurane sedation in the intensive care unit with the anesthetic-conserving device: a comparison with intravenous propofol sedation. Anesth Analg 2009; 108: 1848-54.
22. Spencer EM, Willatts SM, Prys-Roberts C. Plasma inorganic fluoride concentrations during and after prolonged (>24 hr) isoflurane sedation. Effects on renal function. Anesth Analg. 1991; 73: 731-7.
23. Karkouti K, Wijeysundera DN, Yau TM, et al. Acute kidney injury after cardiac surgery: focus on modifiable risk factors. Circulation 2009; 119: 459-502.
24. Tempia A, Olivei M, Calza E, et al. The anesthetic conserving device compared with conventional circle system used under different flow conditions for inhaled anesthesia. Anesth Analg 2003; 96: 1056-61.
25. Soro M, Badenes R, García-Pérez ML, et al. The accuracy of the anesthetic conserving device (AnaConDa®) as an alternative to the classical vaporizer in anesthesia. Anesth Analg 2010; 111: 1176-9.
26. Migliari M, Bellani G, Rona R, et al. Short-term evaluation of sedation with sevoflurane administered by the anesthetic conserving device in critically ill patients. Intensive Care Med 2009; 35: 1240-6.
27. Pickworth T, Jerath A, DeVine R, et al. The scavenging of volatile anesthetic agents in the cardiovascular intensive care environment: a technical report. Can J Anaesth 2013; 60: 38-43.
28. Sackey PV, Martling CR, Nise G, Radell P. Ambient isoflurane pollution and isoflurane consumption during intensive care unit sedation with the Anesthetic Conserving Device. Crit Care Med 2005; 33: 585-90.
29. Marbini HD, Palayiwa E, Chantler J. Active gas scavenging is unnecessary when using the AnaConDa volatile agent delivery system. Intensive Care Soc 2009; 10: 26-8.
30. Bisbal M, Arnal JM, Passelac A, et al. Efficacy, safety and cost of sedation with sevoflurane in the intensive care unit. Ann Fr Anesth Reanim 2011; 30: 335-41.
31. Röhm KD, Wolf MW, Scholllhorn T, et al. Short-term sevoflurane sedation using the Anaesthetic Conserving Device after cardiothoracic surgery. Intensive Care Med 2008; 34: 1683-9.
32. Sackey PV, Martling CR, Granath F, et al. Prolonged isoflurane sedation of intensive care unit patients with the Anesthetic Conserving Device. Crit Care Med 2004; 32: 2241-6.

Cite this article as: Marcos-Vidal JM, González R, García C, Soria C, Galiana M, De Prada B. Sedation with sevoflurane in postoperative cardiac surgery: influence on troponin T and creatinine values. Heart, Lung and Vessels. 2014; 6(1): 33-42.
Source of Support: Nil. Disclosures: None declared.